Carisma’s attraction

Why Wellington Partners picked Carisma for its first macrophage investment

Macrophage immunotherapy play Carisma Therapeutics Inc. has developed biomarkers that it can use to track macrophage activity and tumor response in preclinical and clinical studies, leading Wellington Partners to join its $53 million series A round.

AbbVie Ventures and

Read the full 398 word article

User Sign In